For registration in Saudi Arabia and the rest of the GCC, plan the long-term arm at 30 °C ± 2 °C / 65 % RH ± 5 % RH, with 12 months of data at submission, and run accelerated at 40 °C / 75 % RH for six months. That is the general-case table in the SFDA-hosted GCC stability guideline (DS-G-005, version 3.4), which places the GCC States in climatic zones III and IVa. There is no intermediate arm when long-term is already 30 °C/65 % RH. Everything else in this article is about the places where plants lose time: zone assumptions, excursions, commitments and the post-approval programme.
We assume you already know the ICH Q1A(R2) mechanics. If not, start with our article on running stability programmes, which covers pull points, trending and what inspectors look for in the chamber room. This one is about which conditions your Saudi dossier is judged against, and why.
Zones: What ICH, WHO and the GCC Each Say
ICH Q1A(R2) (Step 4, 6 February 2003) states that the world can be divided into four climatic zones and then limits itself: “This guideline addresses climatic zones I and II.” Its general case gives long-term 25 °C/60 % RH or 30 °C/65 % RH, intermediate 30 °C/65 % RH and accelerated 40 °C/75 % RH, with a footnote that if 30 °C/65 % RH is the long-term condition, “there is no intermediate condition.” ICH therefore tells you nothing about what a hot-climate regulator wants. That gap was meant to be filled by ICH Q1F, but ICH withdrew Q1F.
WHO TRS 1010, Annex 10 (2018) explains what happened. Q1F had fixed 30 °C/65 % RH as the long-term condition for zones III and IV, after a WHO survey of member states. Some zone IV countries then asked for a larger safety margin, several regions revised their own guidelines to as much as 30 °C/75 % RH, and ICH withdrew Q1F and left zone III/IV conditions to the regions and WHO. Annex 10 itself offers three long-term options, 25 °C/60 % RH, 30 °C/65 % RH or 30 °C/75 % RH, “determined by the climatic zone in which the FPP is intended to be marketed”, and repeats the footnote that there is no intermediate condition at 30 °C/65 % RH or 30 °C/75 % RH. Its labelling appendix notes that zone II is 25 °C/60 % RH, zone IVa is 30 °C/65 % RH and zone IVb is 30 °C/75 % RH.
| Source | Climatic zones it covers | Long-term condition |
|---|---|---|
| ICH Q1A(R2), 2003 | I and II | 25 °C/60 % RH or 30 °C/65 % RH |
| WHO TRS 1010, Annex 10, 2018 | I to IVb, by market | 25 °C/60 % RH, 30 °C/65 % RH or 30 °C/75 % RH, by climatic zone |
| SFDA-hosted GCC guideline DS-G-005 v3.4 | GCC States stated as III and IVa | 30 °C/65 % RH (general case) |
Annex 10 has no country-by-country zone table; it points to a separate WHO list of the long-term conditions each member state has identified. For the GCC, the authoritative statement is the one SFDA publishes, not a table lifted from a secondary source.
What the SFDA/GCC Guideline Actually Requires
The guideline we read is SFDA document DS-G-005, version 3.4, whose document-control table dates version 3.4 to 22 August 2022 (the cover shows publication 3 February 2011 and implementation 3 May 2021). Its introduction says it is adapted from ICH and WHO stability guidelines and describes “the core stability data package required for registration” of APIs and finished products in the GCC States. Check sfda.gov.sa for a newer version before you lock a protocol. The points that drive protocol design:
- Zone statement. The glossary footnote reads “GCC States are categorized in climatic zones III & IV a.”
- Conditions (section 3.2.6.1). Long-term 30 °C ± 2 °C/65 % RH ± 5 % RH, 12 months at submission; accelerated 40 °C ± 2 °C/75 % RH ± 5 % RH, 6 months. Generic products marketed in the country of origin must submit long-term data supporting the complete proposed shelf-life. “Alternative storage conditions can be used if justified.”
- Batches. Three primary batches for an API (3.1.3). For an FPP, version 3.4 deleted the earlier allowance of two batches for known-stable conventional products, so plan three.
- Frequency (3.2.5). Normally every three months in year one, every six months in year two, then annually: 0, 3, 6, 9, 12, 18, 24, 36. At least three accelerated time points.
- Semi-permeable packs (3.2.6.3). Aqueous products in semi-permeable containers are evaluated for water loss at 30 °C/35 % RH long-term and 40 °C/NMT 25 % RH accelerated.
- Excursions (3.2.6). Conditions should be monitored and recorded. Excursions beyond tolerance for more than 24 hours should be described in the study report and their effect assessed.
- Labelling (Appendix 2). Stability shown at 30 °C/65 % RH long-term with 40 °C/75 % RH accelerated supports “Store below 30 °C”.
Inspectors do not read this guideline alone. The SFDA GMP guide (version 4.4) adds the post-approval side in Chapter 6, paragraphs 6.26 to 6.35: a written ongoing stability protocol, at least one batch per year per strength and primary pack type unless justified, and results made available to the Qualified Person, who relies on them at certification (see our note on batch release and the QP in Saudi Arabia). Chamber monitoring data are GMP records too; our note on SFDA GMP and Annex 11 covers how the computerised-systems annex applies to them.
The Zone IVa Versus IVb Question
It keeps coming up, usually because a global product team has a single “hot and humid” protocol at 30 °C/75 % RH and asks whether the Saudi dossier needs it. On the primary text, the answer is no. SFDA’s own guideline classes the GCC as III and IVa, and its general-case table is 30 °C/65 % RH. That is the basis we recommend: zone IVa/III, 30 °C/65 % RH long-term.
Two caveats from the sources. First, the guideline allows alternative conditions “if justified”, so a study at 30 °C/75 % RH is not rejected on that ground; it just is not what the table asks for. Second, WHO Annex 10 says zone IVa “may be acceptable in lieu of IVb when humidity is not an issue, for example, for storage in glass containers”. The reverse also applies in practice. A product that is going to IVb markets as well as the GCC will usually carry one 30 °C/75 % RH arm for those markets and a 30 °C/65 % RH arm for the Saudi dossier. A single arm at the more severe condition may be acceptable to a reviewer, but you are then arguing the point rather than citing the table.
Where we disagree with common practice is the habit of choosing the severest condition to be safe. The stored data then fix your label statement and your shelf-life. A product that passes at 30 °C/65 % RH but fails at 30 °C/75 % RH on dissolution can lose months of shelf-life for a condition the regulator never asked for.
Accelerated and Intermediate Conditions
Accelerated is 40 °C/75 % RH for six months in all three documents. Intermediate is where teams go wrong. Under ICH Q1A(R2) it exists only when long-term is 25 °C/60 % RH and significant change appears at accelerated; at 30 °C/65 % RH there is none. The GCC guideline’s general-case table has no intermediate row. If you file with long-term at 30 °C/65 % RH, an intermediate arm adds chamber space and testing with no regulatory function. The exception is a global protocol built on a 25 °C/60 % RH long-term arm for other markets: there, a significant change at accelerated triggers 30 °C/65 % RH testing, and that data happens to be useful for the GCC file.
“Significant change” is defined in the GCC glossary the usual way: a 5 % or greater change in assay from initial, any degradation product beyond its criterion, failure of appearance, physical or functionality criteria, and, as appropriate, pH or dissolution for 12 dosage units.
Commitment Batches
Section 3.2.7 is short and often misread. If long-term data on the primary batches do not cover the proposed shelf-life, you commit to continue those studies after approval. If the submission has fewer production batches than required, you also commit to put additional production batches on long-term study, to at least three in total. If it has none, the first two or three production batches go on study. The protocol is the same as the primary batches’ unless a change is scientifically justified.
Where this fails: the commitment is written in the dossier, then nobody owns it. The first commercial batch is then never charged, or goes into a different condition because the chamber was full. Treat each commitment as a tracked obligation with a named batch, a charge date and a due date for the data, and review it at management review. A provisional 24-month shelf-life on thin data (3.2.8) comes with exactly this obligation: you must keep running long-term studies to the proposed shelf-life.
In-Use Stability
Section 3.2.10 applies to multi-dose products, anything opened and used over days or weeks. Registration should include in-use data on which the in-use shelf-life is based, or a justification for why none is set. Test at least two pilot-scale batches, at least one chosen towards the end of its shelf-life (or, failing that, one batch at the final point of the submitted study, with a commitment to submit end-of-shelf-life results). Design the test to simulate real use: withdraw doses at realistic intervals, by the method in the leaflet, under normal environmental conditions of use, and test physical, chemical and microbial attributes including preservative content. The in-use period and storage recommendation then go into the SPC, the leaflet and the label.
The deficiency we see most is an in-use study run on a fresh batch from a protocol written for the primary container, with the product opened once and tested once. That does not simulate use.
Common Deficiencies
These are the patterns we see repeatedly in stability programmes, several of them straight from the guideline text:
- Long-term at 25 °C/60 % RH only in a file meant for the GCC, with no argument for why it covers zone IVa.
- Fewer than 12 months of long-term data at submission where the guideline expects 12, or a generic filed without data covering the full proposed shelf-life.
- Unassessed excursions. A chamber was out of tolerance for more than 24 hours and the study report is silent (3.2.6).
- A storage statement that does not match the data, for example “Store below 25 °C” on a product whose tested condition is 30 °C/65 % RH.
- Commitment batches with no owner, as above.
- The ongoing programme is a calendar of one-off studies. The GMP guide wants a written protocol, one batch per year per strength and pack, and trend analysis; a confirmed out-of-specification result or significant atypical trend is reported immediately to the competent authority (GCC 3.2.12).
- Methods not shown to be stability-indicating. The guideline requires validated, stability-indicating procedures.
- No in-use data or justification on a multi-dose product.
- Retest period for an API beyond five years from manufacture (3.1.1).
Running the Programme in Software
None of the above needs special software, but pull dates, chamber logs and commitment tracking across a few dozen studies are where spreadsheets give out. In stability LIMS software, the CORPEX LIMS Stability module keeps storage conditions as master data (temperature, humidity, tolerance, condition type, climatic zone, default pull points), and a protocol picks its conditions and pull points per station. Each station of a protocol takes its condition from that master list, so the choice of 30 °C/65 % RH for a Saudi study is made and approved in the protocol, as it should be. Chamber excursions are recorded and every exposed study gets its own impact assessment. If you are comparing options, our page on a LIMS for Saudi laboratories sets out the wider context. Qualification, validation and your SOPs remain yours.
Sources
All documents read on 16 November 2026.
- SFDA-hosted GCC stability guideline, document DS-G-005, version 3.4 (document control 22 August 2022): sfda.gov.sa (glossary, sections 3.1.1, 3.1.3, 3.2.5 to 3.2.8, 3.2.10, 3.2.12, Appendix 2)
- SFDA Guide to Good Manufacturing Practice for Medicinal Products, version 4.4, Chapter 6, 6.26 to 6.35: sfda.gov.sa
- ICH Q1A(R2), Stability Testing of New Drug Substances and Products, Step 4, 6 February 2003: ich.org
- WHO Technical Report Series 1010, 2018, Annex 10, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products: who.int
Frequently Asked Questions
Is Saudi Arabia zone IVa or IVb for stability testing?
The GCC stability guideline hosted by SFDA (document DS-G-005, version 3.4) states that GCC States are categorised in climatic zones III and IVa. Its general-case long-term condition is 30 °C ± 2 °C / 65 % RH ± 5 % RH. That is the zone IVa condition. Zone IVb, 30 °C/75 % RH, is not the stated requirement for the GCC, although alternative conditions may be used if justified.
What long-term storage condition does SFDA require for registration?
30 °C ± 2 °C / 65 % RH ± 5 % RH, with a minimum of 12 months of data at submission for the general case, and accelerated testing at 40 °C ± 2 °C / 75 % RH ± 5 % RH for 6 months. Generic products that are already marketed in the country of origin must submit long-term data covering the whole proposed shelf-life.
Do I need an intermediate condition for Saudi Arabia?
Not when long-term is 30 °C/65 % RH. ICH Q1A(R2) and WHO TRS 1010 both say there is no intermediate condition if the long-term condition is 30 °C/65 % RH or 30 °C/75 % RH. The GCC guideline lists only long-term and accelerated conditions in its general-case table.
What is a stability commitment and when is it needed?
If the long-term data on the primary batches do not cover the proposed shelf-life at approval, you commit to continue the studies after approval, and in some cases to add production batches so that at least three are on study. Commitment batches follow the same protocol as the primary batches unless a change is scientifically justified.
Does a multi-dose product need an in-use stability study?
The GCC guideline says registration of a multi-dose product should include in-use stability data, or a justification for why no in-use shelf-life is set. At least two pilot-scale batches are tested, and at least one should be near the end of its shelf-life.
How often are ongoing stability studies required after approval?
The GCC guideline and the SFDA GMP guide both say that, unless otherwise justified, at least one batch per year of each strength and each primary pack type is included in the ongoing stability programme, unless none is produced that year.
Planning a stability programme for an SFDA filing?
See how the CORPEX LIMS Stability module holds protocols, storage conditions, pull points and chamber excursions, with conditions set per protocol.
Explore the stability module